汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
Gritstone Bio’s phase 2 cancer vaccine trial missed the primary endpoint in front-line MSS-CRC; ParrBio/Syncromune HP007(CpG) plus antibody cocktail in prostate cancer (84.6% ORR); Macrogenic B7-H3-ADC phase II results; Profound Bio acquisition by Genmab; Arvinas/Novartis transaction in Androgen Receptor Degrader for Prostate Cancer; ImmunityBio's IL-15 receptor agonist was approved for BCG-unresponsive non-muscle invasive bladder cancer; FDA Grants Accelerated Approval to Ojemda for Pediatric Relapsed/Refractory BRAF+ Low-Grade Glioma;
Alpine acquisition by Vertex (and more about TACI); Nkarta prioritizing CAR-NK therapy for autoimmune diseases and closed $240M PIPE; Cullinan Therapeutics announced strategic expansion into autoimmune diseases and closed $280 PIPE;
Eli Lilly/Regeneron GLP1/Leptin R agonist combo phase II trial for obesity;
Sanofi’s frexalimab showed promising efficacy signal in phase 2 trial of multiple sclerosis; Intra-Cellular Therapies’ Caplyta scored another positive Ph3 readout in major depression disorder, poised to expand its label beyond schizophrenia and bipolar disorder;
Abbvie/Medincell link up in long-lasting injectable therapies;
NYT and The Economist published articles to highlight the potential negative impact of Biosecure Act that target China CDMO like WuXi AppTec and WuXi Biologics.
活动详情
主题：Monthly biotech news discussion -April 2024 in review
时间：2024年04月26日 Fri 9:00 PM（EST）/ 2024年04月27日 周六 早上9:00 AM（北京时间）
地点：zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）
嘉宾：
Jimmy Wang(王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
Yanran He(何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Ethan Xu(徐亦迅), VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Stephen Yan(严顺飞), BD Search & Evaluation @ AstraZeneca
(https://www.linkedin.com/in/shunfei-yan/)
Qinghong Yan(晏庆红), CSO @ Leverna Therapeutics
(http://linkedin.com/in/qinghong-yan)
Leon 'Jun' TANG(唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Haoran Wang(王浩然), CEO @ Weihai Neoland Biosciences Co.,Ltd.
(https://www.linkedin.com/in/hao-ran-wang-228648b)
Lihua Yu(于利华), Chief Data Officer @ fogpharma
(https://www.linkedin.com/in/lihua-yu-5b3337)
Xianbo Zhou(周显波), Founder & CEO @ AstraNeura
(https://www.linkedin.com/in/xianbo-zhou-7b33b76/)
Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)
Yongjiang Hei(黑永疆), Co-CEO @ Biocity Biopharma
( http://linkedin.com/in/yonghei)
Wenjun Wu(Armstrong,吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Jun Wang
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
BioSpark events Calendar:
https://tinyurl.com/tcwy44t6
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
赞 助 机 构
战 略 合 作
BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。
更多精彩，请关注BioSpark公众号
